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Ideal strategies to ameliorate CNS damage should
promote both neuronal survival and axon regenera-
tion. The receptor Neogenin promotes neuronal
apoptosis. Its ligand prevents death, but the result-
ing repulsive guidance molecule a (RGMa)-Neogenin
interaction also inhibits axonal growth, countering
any prosurvival benefits. Here, we explore strategies
to inhibit Neogenin, thus simultaneously enhancing
survival and regeneration. We show that bone
morphogenetic protein (BMP) and RGMa-dependent
recruitment of Neogenin into lipid rafts requires an
interaction between RGMa and Neogenin subdo-
mains. RGMa or Neogenin peptides that prevent
this interaction, BMP inhibition by Noggin, or reduc-
tion of membrane cholesterol all block Neogenin raft
localization, promote axon outgrowth, and prevent
neuronal apoptosis. Blocking Neogenin raft asso-
ciation influences axonal pathfinding, enhances
survival in the developing CNS, and promotes
survival and regeneration in the injured adult optic
nerve and spinal cord. Moreover, lowering choles-
terol disrupts rafts and restores locomotor function
after spinal cord injury. These data reveal a unified
strategy to promote both survival and regeneration
in the CNS.INTRODUCTION
CNS injuries result in permanent functional loss due to the poor
capacity of adult CNS neurons to regenerate axons. This is com-
pounded by the pronounced susceptibility of adult CNS neurons
to undergo apoptotic death when injured. It is therefore impor-
tant to address both neuronal apoptosis and regenerative failure
in the mature CNS (Schwab, 1990). The inability of axons to1146 Cell Reports 8, 1146–1159, August 21, 2014 ª2014 The Authorregenerate is largely associated with (1) a poor intrinsic ability
to regenerate (Liu et al., 2011), and (2) the non-neuronal aspects
of the CNS environment that inhibit axonal elongation. As a
consequence, strategies that promote regenerationmainly focus
on either enhancing the inner capacity of axons to regenerate or
on neutralizing the negative aspects of the environment (Liu
et al., 2011). Following injury, axons are confronted with inhibi-
tors present both in the glial scar (Fawcett and Asher, 1999)
and the myelin (McKerracher et al., 1994; Schwab, 2004; Wang
et al., 2002). Notably, the repulsive guidance molecule a
(RGMa) is present in both the glial scar and the myelin (Schwab
et al., 2005a, 2005b) and accumulates at lesions after traumatic
brain injury, spinal cord injury (SCI), and ischemia (Schwab et al.,
2005a, 2005b).
RGMa is a potent inhibitor of axonal growth in both the
adult and developing CNS (Monnier et al., 2002). It exerts its
repulsive activity through the transmembrane receptor Neoge-
nin (Rajagopalan et al., 2004). In addition to their role in
axonal outgrowth, RGMa and Neogenin are involved in cell
survival. Neogenin is a dependence receptor that causes
death or survival when RGMa is absent or present, respectively
(Matsunaga and Che´dotal, 2004). In the developing chick
brain, Neogenin induces apoptosis in the absence of RGMa.
The RGMa/Neogenin pathway is also an important trigger of
neuronal death in the injured CNS (Koeberle et al., 2010).
Thus, RGMa has two contradictory activities in the regen-
erating CNS: it promotes cell survival, which is an important
positive aspect of its function, but it also inhibits axonal
growth, which is undesirable. Neogenin mediates both effects;
therefore, inhibiting this receptor might promote both sur-
vival and axonal regeneration. However, whether removing
Neogenin would confer these benefits is unknown, and even
if it did, there are no strategies to achieve this goal
pharmaceutically.
The plasma membrane of cells contains a combination of gly-
cosphingolipids and protein receptors organized in microdo-
mains termed ‘‘lipid rafts’’ (Thomas et al., 2004). Lipid rafts
have been implicated in regulating the activity of a plethora of
extracellular receptors and diverse cellular processes. Neurons,s
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C D Figure 1. Neogenin Is Present in Lipid Rafts
(A) Schematic representation of the sequences
used to generate the N-20 and AF1079 antibodies
against Neogenin.
(B) Western blot analysis of brain lysates showing
that N-20 detects one 180 kDa band, whereas
AF1079 recognizes the 180 kDa band and an
N-terminal deletion of Neogenin at 150 kDa.
(C and D) Immunofluorescence images of retinal
growth cone of (C) F-actin (Alexa 488 phalloidin)
and (D) Neogenin. Scale bars, 30 mm.
(E) Composite images of Neogenin (Neog.) stain-
ing, the raft marker CTB, and merged image; yel-
low indicates regions of colocalization. ICQ to
quantify colocalization between Neogenin and
CTBwas calculated as described by Li et al. (2004)
in 12 growth cones. ICQ reflects the ratio of the
number of positive or negative (Ai  a) (Bi  b)
values to the total pixel number minus 0.5 to
derive a 0.5 to +0.5 range. Here, an average ICQ
of 0.27 was computed, which indicates strong
colocalization between Neogenin and CTB. Scale
bars, 30 mm.
(F) Composite images of Neogenin (AF1079), the
RGMa, and merged image; yellow indicates
regions of colocalization. An average ICQ of
0.32 was computed, which indicates strong
colocalization between Neogenin and RGMa.
Scale bars, 30 mm.
(G) Chick brain gradient fractionation showing that
Neogenin (arrowhead) localizes with RGMa and
raft marker Flotillin. Transferrin receptor (TfR) was
used a heavy fraction marker.for example, require lipid rafts to react to guidance signals pro-
vided by the extracellular cues brain-derived neurotrophic factor
(BDNF) or Semaphorin (Guirland and Zheng, 2007). Interestingly,
the Netrin-1 receptor, Deleted in Colorectal Cancer (DCC), which
is a homolog of Neogenin, requires rafts to guide neurons and
control apoptosis (Furne et al., 2006). Although RGMa, which
is a glycosylphosphatidylinisotol (GPI)-anchored protein, is
known to accumulate in lipid rafts (Monnier et al., 2002), it is
hitherto not known if Neogenin similarly relies on its presence
in these subdomains to either transmit guidance signals or con-
trol death.
Here, we dissected the factors that affect localization of
Neogenin in lipid rafts and the consequences for neuronal sur-
vival and axonal regeneration. We show that selective interac-
tion between the immunoglobulin domain in Neogenin (4Ig)
and the N-terminal part of RGMa (N-Raft) triggers bone
morphogenetic protein (BMP)-mediated Neogenin recruitment
to lipid rafts. Using a peptide strategy to prevent N-RGMa-
dependent relocation of Neogenin to lipid rafts, we show that
all receptor functions are dependent on its association withCell Reports 8, 1146–1159,rafts. Moreover, we show that modifying
lipid rafts by depleting cholesterol pro-
motes neuronal survival and axonal
regeneration after optic nerve injury and
SCI. Strikingly, blocking Neogenin trans-
port into lipid rafts using either our pep-tide-based strategy or cholesterol depletion restored locomotor
functions after SCI.
RESULTS
Neogenin Is Present in Lipid Rafts in Growth Cones
To gain insights into the role of Neogenin in the developing CNS,
its expression in brain membranes (embryonic day 8 [E8]) was
examined by western blots. An antibody against the entire extra-
cellular domain of Neogenin (AF1079) detected two bands at 180
and 150 kDa, whereas the antibody against theN terminus (N-20)
identified only the 180 kDa band (Figures 1A and 1B), suggesting
that brain membranes contain full-length Neogenin (180 kDa)
and an N-terminal truncation (150 kDa) that lacks some of the
4Ig repeats. Recent studies indicate that diverse receptors
concentrate in cholesterol-rich raft microdomains to elicit
cellular response to extracellular signals (Guirland et al., 2004).
So far, there is no direct evidence that Neogenin localization
in lipid rafts is critical to growth cone response to RGMa. To
test this possibility, we first examined Neogenin membraneAugust 21, 2014 ª2014 The Authors 1147
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Domain in Neogenin and the N-Terminal
Part of RGMa Recruits Neogenin to Lipid
Rafts
(A) RGMa proteins were incubated on plates
coated with 4Ig- or 6FNIII-AP (binding: , base
line; ++, >5 3 base line) (quantitative analysis
for this experiment is presented in Figure S2). One
C- and one N-RGMa domain (N-RGMa77–113)
interacted with 6FNIII. One N-RGMa domain
(N-Raft) interacted with 4Ig.
(B) Supernatants (Sup.) from cells expressing His-
6FNIII or His-4Ig were pulled down (i.p.) with beads
coated with N-Raft, N-RGMa50–99, and N-inh.
Western blot was then performed with a His anti-
body to reveal whether or not His-6FNIII or His-4Ig
interacted with the coated beads. This showed
that His-6FNIII was pulled down by N-inh.,
whereas His-4Ig was pulled down by N-Raft.
Western blot on cell supernatants was performed
to demonstrate that the same amount of His-FNIII
and His-4Ig was used to carry out the pull-down.
IP, immunoprecipitation.
(C and D) Images (C) and quantification (D) of
retinal explant outgrowth on laminin (Lam.) and
laminin plus N-RGMa or N-RGMa protein domains
show that only N-RGMa and N-inh. inhibit
axonal growth. Data are average ± SEM (n = 3
independent experiments). *p < 0.0001. Scale
bars, 100 mm.
(E) Chick brains were injected with control peptide
(Ctrl; N-RGMa50–99), 4Ig, N-Raft, or Noggin 1 day
before preparing membrane fractionations. In
control experiments, Neogenin localizes to the
Flotillin/RGMa-containing lipid raft fraction (red
boxes). 4Ig, N-Raft, or Noggin shifts Neogenin to
heavy fractions.localization. In confocal images, staining performed with an
antibody against the N-terminal part of Neogenin exhibits a
punctate staining pattern in the growth cone of retinal ganglion
cells (RGCs) (E8; Figures 1A–1D). These punctate structures
colocalized with the raft markers, cholera toxin subunit B (CTB)
and RGMa (Figures 1E and 1F), with computed intensity correla-
tion quotients (ICQs) of 0.27 and 0.32, respectively, suggesting
that Neogenin significantly associates with RGMa (p = 0.005)
and rafts (p = 0.0002) (Li et al., 2004). In control experiments, in
which the axons were stained with CTB and F-actin, the
computed correlation quotient was 0.05, indicating segregation
of both stains (Figure S1). To corroborate these findings, we
characterized the abundance of Neogenin in isolated lipid rafts
from chick brain membrane. Indeed, Neogenin was recovered
in fractions 2–4 that are enriched in two lipid raft markers, Flotillin
(Maliszewska-Cyna et al., 2010) and RGMa (Monnier et al.,
2002), but not in the nonraft fractions that contain the heavy
fraction marker, transferrin receptor (Guirland et al., 2004; He´r-
incs et al., 2005) (Figure 1G). We next treated embryos with
methyl-b-cyclodextrin (MbCD) to deplete membrane choles-
terol, which is known to disrupt lipid rafts (Grosse et al., 1998),
and performed fractionations of brain samples. MbCD shifted1148 Cell Reports 8, 1146–1159, August 21, 2014 ª2014 The AuthorNeogenin to nonlipid raft fraction populated by transferrin recep-
tor (Figure S1C).
Interaction betweenN-Raft andNeogenin-4Ig Regulates
Neogenin Presence in Lipid Rafts
In chondrocytes, there is evidence that RGMs may regulate
Neogenin association with lipid rafts; however, the mechanisms
that regulate this process remain elusive (Zhou et al., 2010). We
hypothesized that a yet unidentified interaction between Neoge-
nin and RGMa is involved in Neogenin recruitment toward lipid
rafts. To search for such a domain, we fused the 4Ig and 6FNIII
domains of Neogenin to alkaline phosphatase (AP) and analyzed
binding to various RGMa peptides in an ELISA (Figure 2A).
Similar to published data (Rajagopalan et al., 2004), 6FNIII, but
not 4Ig, interacted with full-length RGMa (Figure 2A). However,
we discovered an interaction between the 4Ig domain and
the N-terminal part of RGMa (Figure 2A). Because we found
that the N-terminal part of RGMa also interacts with the fibro-
nectin domain in Neogenin (Tassew et al., 2012), we asked
whether distinct N-terminal regions bind 4Ig and 6FNIII.
Interestingly, a peptide spanning aa 28–73 (which we will refer
as N-Raft) interacted with 4Ig-AP, whereas a peptide spannings
aa 77–113 (N-inh.) interacted with 6FNIII-AP. In complementary
experiments, N-Raft-AP bound to 4Ig and not 6FNIII, whereas
N-inh.-AP interacted with 6FNIII but not 4Ig (Figure S2). Consis-
tent with the ELISA data, 6FNIII and 4Ig were pulled down by
N-inh. and N-Raft-coated beads, respectively (Figure 2B). To
assess the specificity of the interaction between Neogenin 4Ig
and N-Raft, we checked whether DCC, the closest Neogenin
homolog, interacted with N-Raft. No significant interaction was
observed between DCC-4Ig and N-Raft (Figure S2C).
To assess whether these Neogenin-RGMa interactions are
biologically relevant, we performed outgrowth experiments
using RGMa peptides as substrates (Figure 2C). Full-length
N-RGMa and the N-inh. fragments caused a 3- to 4-fold
decrease in axonal growth compared to controls (51.5.5 ±
3.0 mm and 88.1 ± 13.3 mm versus 238.1 ± 9.3 mm; Figures 2C
and 2D). Because both N-RGMa and N-inh. interact with 6FNIII,
this agrees with our previous findings that RGMa proteins must
interact with the 6FNIII domain to inhibit retinal axon growth
(Tassew et al., 2012). When the N-raft fragment was used as a
substrate, it had no effect on axonal outgrowth (Figures 2C
and 2D). These data indicate that, unlike the N-inh.-6FNIII inter-
action, the contact described here between N-Raft and the 4Ig
portion of Neogenin does not inhibit axonal outgrowth in trans.
To assess whether the purpose of the N-Raft and 4Ig interac-
tion might be to recruit Neogenin into lipid rafts, we tested
whether deleting these RGMa and Neogenin domains would
prevent Neogenin association with rafts (Figure S2). In human
embryonic kidney 293 (HEK293) cells cotransfected with Neoge-
nin and RGMa and treated with BMP2, which promotes Neoge-
nin recruitment to lipid rafts (Zhou et al., 2010), Neogenin was
found in the raft fraction. In contrast, although deletion mutants
of Neogenin (4Ig-del) and RGMa (N-Raft-del) were normally tar-
geted toward the cell surface (data not shown), they were not re-
cruited to the raft fractions (Figure S2). We surmised that if the
interaction between 4Ig andN-Raft is indeed required for Neoge-
nin presence in lipid rafts, overexpressing recombinant 4Ig and
N-Raft to compete with endogenous domains should displace
Neogenin from rafts toward the nonraft fractions. N-Raft, 4Ig,
or control peptide (N-RGMa50–99) was injected into the optic
tectum at E8, and the tecta were collected a day later for frac-
tionation analyses. As expected, full-length Neogenin localized
exclusively to the raft fraction in controls (N-RGMa50–99). Strik-
ingly, N-Raft and 4Ig relocalized Neogenin from rafts to the heavy
fractions (Figure 2E). Because Neogenin presence in lipid rafts is
BMP dependent, we extended our analysis by injecting the
BMP chelator Noggin into chick brains. Similar to the effects of
4Ig and N-Raft, Noggin evicted Neogenin from rafts (Figure 2E).
Together with the in vitro findings, these in vivo results indicate
that an interaction between the 4Ig domain in Neogenin and
the N-Raft domain in RGMa is necessary to recruit Neogenin
to lipid rafts.
Knockdown Analysis Reveals a cis Interaction between
RGMa and Neogenin
Previously, we showed that the CNS contains three RGMa iso-
forms (N-RGMa, C-RGMa, and RGMaD) that inhibit axonal
outgrowth in trans (Tassew et al., 2012). Thus, when provided
as the growth substrate, each of these RGM peptides blocksCelaxon growth. Moreover, they achieve this by interacting with
the Neogenin fibronectin domain (Figures 2A–2D) (Tassew
et al., 2012). Our peptide and deletion analysis (Figures 2E
and S2) indicate that interaction between Neogenin 4Ig and
N-Raft recruits Neogenin into lipid rafts. We wondered whether
this interaction occurs in cis or trans. RGMa localizes to lipid rafts
through its GPI anchor (Monnier et al., 2002); thus, it follows that
it would recruit Neogenin through a cis interaction. Consistent
with this notion, our data show that Neogenin and RGMa are
colocalized in the growth cone (Figure 1F), and when the
N-Raft peptide is provided as a growth substrate (i.e., in trans),
it does not block axonal outgrowth (Figure 2D). As a further
test, we silenced RGMa in the growth cone by delivering small
hairpin RNA (shRNA) into the E2 chick eye and measured
outgrowth on each of the three RGMa proteins using explants
from transfected E7 retinas. Transduction of shRNA in the eye
would only disrupt putative cis RGMa interaction with Neogenin
in RGCs without affecting trans interactions between the growth
cone and RGMa provided exogenously as substrate.
Two different shRNAs that suppressed endogenous RGMa
(shRNA21 and shRNA37; Figure S5) enhanced retinal explant
outgrowth on N-RGMa substrate by 3.1 and 2.8 times, respec-
tively, relative to control shRNA (Figures 3A and 3B). Similarly,
silencing of RGMa led to a 2.8- to 3.4-fold increase in axonal
growth on C-RGMa and RGMaD (Figures 3A and 3B). In rescue
experiments, cotransfection with mouse RGMa, resistant to
shRNA37, restored the inhibitory activity of RGMa proteins in
dissociated RGCs treated with shRNA37 (Figure S3). Therefore,
the result obtained with RGMa shRNA is not an off-target effect.
Altogether, our data indicate that in addition to the established
trans interaction, a cis interaction between RGMa and Neogenin
is also required to inhibit axonal outgrowth.
We hypothesized that this cis interaction between RGMa and
Neogenin occurs between 4Ig and N-Raft. If so, these peptides
could be used as blocking peptides and should restore axonal
growth in retinal explants grown on RGMa proteins. Indeed,
the addition of 5 mg/ml of either 4Ig (Figures 3A and 3C) or
N-Raft (Figures 3A and 3D) to the medium blocked the inhibitory
effects of RGMa proteins and restored outgrowth. Together,
these data suggest that a cis interaction between the Neogenin
4Ig domain and N-Raft is required to inhibit axonal growth.
RGMa Inhibition Requires Neogenin Association with
Lipid Rafts and BMPs
Because the interaction between 4Ig and N-Raft regulates Neo-
genin association with lipid rafts (Figure 2E), the experiments
presented above suggest that Neogenin must be present in lipid
rafts to inhibit axonal growth. To address this issue, we used
agents that disrupt lipid rafts: 10 mMMbCD or 2 U/ml of choles-
terol oxidase (CO). Both treatments restored outgrowth to
control values, when axons were cultured on RGMa proteins
(Figures 3A, 3E, and S3D). Thus, the axonal response to RGMa
is triggered by Neogenin transit to rafts.
Our data suggest that in the developing CNS, Neogenin
recruitment into lipid rafts depends on BMPs (Figure 2E). If so,
Noggin should affect the axonal response to RGMa proteins.
As expected, axonal outgrowth was unaffected by laminin alone
but was markedly reduced by N-RGMa, C-RGMa, and RGMaDl Reports 8, 1146–1159, August 21, 2014 ª2014 The Authors 1149
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(Figures 3A and 3F). Noggin restored outgrowth in retinal ex-
plants (E8) exposed to each individual RGMa to control values
(Figures 3A and 3F). These data suggest that a similar mecha-
nism, which is dependent on BMP, underlies the Neogenin-
mediated response to all three RGMa proteins. Collectively,
these results indicate that RGMa together with BMP(s) regulates
Neogenin transport into lipid rafts, and this link is required to
mediate axon growth inhibition by RGMa.
Neogenin Requires Lipid Rafts for Correct Axonal
Pathfinding
To assess the biological relevance of the interaction between
4Ig and N-Raft on axonal paths in vivo, we ectopically ex-
pressed both peptides and compared pathfinding to controls
(N-RGMa50–99). To ensure that treatments affect growing axons
and not their environment, we performed electroporation and
narrowed the application of the electric field to the optic vesicle
at E2, thus restricting expression to the eye and to retinal axons
(Figure 3G). In control experiments, all retinal axons established
arborization within a well-defined terminal zone (Figure 3H). As a
positive control, we electroporated an shRNA that silences
RGMa, which we have shown perturbs axonal paths (Figure 3I;
Tassew et al., 2008). Consistent with our hypothesis, 100%
(eight of eight) of the 4Ig and 85.7% (six of seven) of the N-Raft
electroporations caused aberrant paths (Figures 3J and 3K).
Thus, the 4Ig-N-Raft interaction that is critical for Neogenin local-
ization to lipid rafts in vitro is also essential for axonal pathfinding
in vivo. Together with the outgrowth experiments (Figures 3A–
3F), these data suggest a model for the BMP, RGMa, and
Neogenin action in which RGMa binding in cis to Neogenin,
aided by BMP, translocates the receptor to lipid rafts, and this
is essential for the subsequent transRGMa-Neogenin interaction
that inhibits axons (Figure 3L). Blocking translocation to lipid
rafts with Noggin, N-Raft peptide, 4Ig peptide, RGMa knock-
down in the growth cone, or cholesterol depletion provides five
strategies for stimulating axonal growth (Figure 3L).
Neogenin Requires Lipid Rafts to Induce Cell Death
Although neutralizing RGMa increases axonal growth, this also
has the undesirable effect of activating the prodeath function
of Neogenin (Koeberle et al., 2010). We therefore reasoned
that preventing Neogenin transport into lipid rafts might simulta-Figure 3. Neogenin Association with Lipid Rafts Is Required for RGMa
(A) Temporal explants cultured on N-RGMa and treatedwith 4Ig (1 mg/ml), N-Raft (
and Noggin (100 nM). Scale bar, 60 mm.
(B–F) Explants were grown on laminin (Ctrl), on laminin plus N-RGMa, C-RGMa, or
(E) MbCD and CO, and (F) Noggin (Nog.). Data are average ± SEM (n = 3 indepe
(G) Schematic representation of in vivo experiments in the chick visual pathway. Th
constructs, and at E17, tracing was performed from the eye to the optic tectum.
(H) Control experiments using N-RGMa50–99, which does not interact with Neog
terminal zone (TZ).
(I–K) Electroporation of (I) RGMa-shRNA-, (J) N-Raft-, or (K) 4Ig-perturbed axona
TZ (arrowheads). Scale bar, 100 mm.
(L) Schematic representation of the action of treatments presented above. The 4Ig
a BMP-dependent recruitment of Neogenin into lipid rafts. Once in lipid rafts, N
association with lipid rafts abolish axonal inhibition. These treatments are (1) ch
addition of N-Raft peptides; (3) masking of the N-Raft site on RGMa with the
ShRNA37); and (5) disrupting lipid rafts using cholesterol depletion (MbCD and C
Celneously promote regeneration and survival. To determine
whether Neogenin requires lipid rafts to induce apoptosis, we
transfected HEK293 cells with Neogenin and measured death
by trypan blue exclusion assay. In this assay, we used HEK293
cells that stably express RGMa (Figure S4). Neogenin elevated
cell death by 2-fold above that seen in mock cells (Figure 4A).
When Noggin, 4Ig, N-Raft, or MbCD was added to the medium
of Neogenin-transfected cells, cell viability was improved 2-
to 3-fold, indicating that lipid rafts are required for Neogenin-
induced death (Figure 4B).
We have previously shown that RGMa is expressed in the
developing chick neural tube (Matsunaga et al., 2004). Thus, to
investigate whether Neogenin requires rafts for its prodeath
function in vivo, we analyzed apoptosis in neural tubes of chick
embryos (E2). A GFP construct was electroporated with plas-
mids that expressed either mock or Neogenin, and apoptosis
was assayed by TUNEL staining. In contrast tomock expression,
which did not induce apoptosis (Figure S4), numerous TUNEL-
positive cells were observed in GFP-Neogenin-transfected cells
(Figures 4C and 4D). This proapoptotic effect of Neogenin was
abolished when either 4Ig or N-Raft was injected into the tecta
following Neogenin electroporation. 4Ig or N-Raft reduced the
number of TUNEL-positive cells by 18-fold (from 432 ± 23 to
23 ± 4) and 4-fold (from 432 ± 23 to 103 ± 8), respectively (Fig-
ure 4D). These results show that Neogenin presence in lipid rafts
is mandatory to cause apoptosis in the developing brain.
Neogenin Requires Lipid Rafts to Induce Apoptosis in
Injured Retinal Neurons
Our data underpin the obligatory role of lipid rafts for RGMa/
Neogenin function during brain development. Because the
RGMa/Neogenin pathway is a critical trigger of neuronal death
in the injured CNS (Koeberle et al., 2010), localization of Neoge-
nin in rafts might also be essential to its pathophysiological roles.
We tested this notion in retinal organotypic cultures wherein
axotomy of RGCs deprives cells of trophic factors, thus inducing
apoptosis. Cell death was detected using propidium iodide (PI),
and all images were taken at the same intensity with the RGC
layer in focus. Cell death was gauged by measuring the relative
PI intensity of wholemounts. The presence of either 4Ig or N-Raft
in the medium significantly reduced cell death (by 40%) (Fig-
ures 4E and 4F). Perturbing rafts with either MbCD or COInhibitions
1 mg/ml), RGMa shRNAs (shRNA21 and shRNA37), MbCD (10mM), CO (2 U/ml),
RGMaD, and treatedwith (B) RGMa shRNA21 and shRNA37, (C) 4Ig, (D) N-Raft,
ndent experiments). *p < 0.005.
e right eye was electroporated at E2 with plasmid expressing RGMa/Neogenin
The inset denotes the area presented in (H)–(K).
enin. Axonal path is intact, and all fibers established terminal arbors into the
l paths with numerous fibers establishing terminal arbors outside the predicted
domain in Neogenin interacts with the N-terminal part in RGMa (N-Raft) to allow
eogenin can transduce axonal inhibition. Treatments that prevent Neogenin
elating of BMPs with Noggin; (2) masking of the 4Ig site on Neogenin with the
addition of 4Ig peptides; (4) silencing of RGMa with shRNAs (shRNA21 and
O).
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Figure 4. Neogenin Requires Lipid Rafts to Induce Cell Death
(A) HEK293 cells that stably express RGMa (Figure S4) were transfected with
empty plasmid (Ctrl) or Neogenin (Neo). Neogenin induced cell death (arrows)
when compared to control.
(B) Quantification of cell death in Neogenin-transfected cells that were incu-
bated in BSA (Neo+Ctrl), 4Ig (1 mg/ml), N-Raft (1 mg/ml), Noggin (100 nM), or
MbCD (10 mM). Treatments that prevent Neogenin association with lipid rafts
significantly rescued Neogenin-induced cell death. Data are average ± SEM
(n = 3 independent experiments). *p < 0.0001.
1152 Cell Reports 8, 1146–1159, August 21, 2014 ª2014 The Authorsimilarly enhanced cell survival by50% versus control (Figures
4E and 4F).
Higher levels for both Neogenin and RGMa have been
observed in the retina following injury (Schnichels et al., 2012).
Furthermore, we have shown that RGMa and Neogenin cause
apoptotic death of RGCs in vivo following axotomy (Koeberle
et al., 2010). To determine whether Neogenin requires lipid rafts
in this context, 4Ig or N-Raft was injected intraocularly, and cell
survival was measured 14 days after axotomy. Both 4Ig (682 ±
21 cells/mm2) and N-Raft (652 ± 24 cells/mm2) increased RGC
survival 2-fold versus control (361 ± 19 cells/mm2) (Figures
4G–4I). Likewise, systemic application (intraperitoneal [i.p.]) of
MbCD also increased RGC survival 2-fold (Figures 4G and
4J). CO is not stable and could not be tested in vivo. Collectively,
these results support our hypothesis that Neogenin-induced
apoptosis in the injured CNS relies on its association with lipid
rafts, which is governed by interaction between its 4Ig domain
and N-Raft.
Neogenin Requires Lipid Rafts to Hamper Axonal
Regeneration after SCI
Thus far, our in vitro results show that segregating Neogenin
from lipid rafts supports axonal outgrowth and halts neuronal
death in the developing CNS (Figures 3 and 4). We also observed
improved survival of RGCs following axotomy in vivo (Figures
4G–4J). Although RGMa is expressed by radial glia cells during
development and acts as a guidance molecule (Monnier et al.,
2002), it is expressed by reactive astrocytes and oligodendro-
cytes in the injured CNS (Hata et al., 2006; Schwab et al.,
2005a). In both the developing and the regenerating CNS,
RGMa works as an inhibitor of axonal growth. Thus, having
shown that preventing Neogenin association with lipid rafts sup-
presses the inhibitory function of the RGMa/Neogenin pathway
in developing RGCs, we extended our study tomodels of injuries
in which this pathway impedes regeneration. We studied regen-
eration after SCI in a rat spinal cord compression model that
closely mimics human SCI (Rivlin and Tator, 1978). All animal
procedures were reviewed and approved by local animal care(C and D) Representative images (C) and quantification (D) of cell death in chick
E5 tecta electroporated with GFP- and a Neogenin-expression plasmid and
then injected with N-RGMa50–99 (Ctrl; 1 mg/ml), 4Ig (1 mg/ml), or N-Raft (1 mg/ml)
and subjected to TUNEL assay. 4Ig or N-Raft significantly reduced the number
of TUNEL-positive cells caused by Neogenin. Data are average ± SEM from
three different tecta/conditions (*p < 0.001). Scale bars, 100 mm.
(E and F) Representative images (E) and quantification (F) of retinal whole
mounts incubated for 4 days with control peptide (1 mg/ml), 4Ig (1 mg/ml),
N-Raft (1 mg/ml), or MbCD (10 mM), and dead cells were stained with PI.
Images from nine whole mounts per condition from three independent ex-
periments were taken at the same intensities, and the fluorescence was
measured using ImageJ. 4Ig, N-Raft, and MbCD significantly reduced cell
death in retinal whole mounts. Scale bars, 500 mm.
(G) Fluorescence micrographs of flat-mounted retinas depicting FluoroGold-
labeled RGCs in injured retinas at 14 days following axotomy. Control retinas
(Ctrl) had few surviving RGCs. 4Ig, N-raft, and MbCD increased cell survival.
Scale bar, 200 mm.
(H) Representations of the retinal areas selected in our analyses.
(I and J) Quantification of the density of surviving RGCs at 14 days post-
axotomy showing that (I) 4Ig and N-raft and (J) MbCD significantly increased
RGC survival. Data are average ± SEM (n = 6 eyes). *p < 0.01.
s
committees in accordance with guidelines established by the
Canadian Council on Animal Care. Functional recovery was
monitored weekly using the Basso, Beattie, Bresnahan (BBB)
locomotor rating scale, motor subscore, and ladder walk tests
(Basso et al., 1995; Metz and Whishaw, 2002). Treatment with
either 4Ig (intravenous [i.v.]) or MbCD (i.p.) showed significant
functional recovery asearly as 2–3weekspost-SCI, asevidenced
by a higher BBB score andmotor subscore compared to controls
(Figures 5A, 5B, 5D, and 5E). Hindlimb coordination was as-
sessed using the ladder walk test where footfalls are considered
errors, and thus, a higher score reflects poorer coordination.
Compared to controls, rats injected with 4Ig had fewer footfalls
(Figure 5C). A similar pattern of functional improvement was
also observed in rats injectedwithMbCD (Figures 5D–5F). Impor-
tantly, staining for astrocytes indicated that treatments with 4Ig
and MbCD did not affect populations of these cells. Thus,
improvement of motor functions seen could have resulted from
improved neuronal survival or axon regeneration (Figure S5).
To ensure that the effect observed with 4Ig resulted solely from
anaction of this peptide at the injury site, weperformed local intra-
thecal application using ALZET osmotic minipumps. To lower
spontaneous recovery, a stronger clip was used to perform com-
pression SCI (26g versus 20g). Similar to systemic application,
local application of 4Ig showed significant functional recovery as
early as 2–3 weeks post-SCI as evidenced by a higher BBB score
(Figure 5G). Here also, hindlimb coordination was significantly
improved, and rats locally injected with 4Ig had fewer footfalls
(Figure 6H). We also tested the effects of MbCD on locomotor
recovery in older animals (>7 months; n = 4), post-SCI. Similar to
the results with young animals, MbCD treatment led to marked
improvements (+6.8 BBB points versus control; Figure S6C).
Thus, hindering the association of Neogenin with lipid rafts
robustly stimulates functional locomotor recovery following SCI.
Neuronal Sparing and Motor Axon Regeneration
Neuronal loss after SCI results in loss of muscle control
and eventual paralysis. Furthermore, RGMa/Neogenin triggers
neuronal death in injured CNS (Koeberle et al., 2010). Thus, we
asked if blocking Neogenin association with lipid rafts could
halt neuronal loss and accelerate axonal regeneration after SCI
and the ensuing functional recovery. Injured rats received sys-
temic application of either 4Ig or MbCD for 6 weeks, and peri-
lesional neurons were quantified with the neuronal marker
NeuN. 4Ig or MbCD treatment increased the number of peri-
lesional neurons compared to controls by 2-fold (Figures 5I–
5M). Intrathecal application of 4Ig over a 6-week period resulted
in a similar increase (2-fold) of NeuN-positive cells in cross-
sections of the cord (Figures 5N–5P and S5E). Measurements
revealed that the lesion volumes for 4Ig- and MbCD-treated
animals did not significantly vary when compared to controls
(Figure S5D). Thus, this supports the notion that blocking Neoge-
nin association with lipid rafts attenuates neuronal loss following
SCI, which parallels our findings after optic nerve injury.
The inability of CNS axons to regenerate is largely due to inhib-
itors present in the myelin that are not conducive to regeneration
(Fawcett and Asher, 1999). To evaluate whether the improved
behavioral outcome resulted from axonal regeneration, we per-
formed anterograde tracing of cortico-spinal tracts (CSTs) byCelinjecting biotin dextran amine (BDA) into the motor cortex (Fig-
ure 6). Only one control animal showed a single regenerating
fiber that extended beyond the injury site (cavity). By contrast,
all 4Ig- and MbCD-treated animals had fibers protruding beyond
the cavity, and some extended a fewmillimeters beyond this site
(Figures 6A and 6B). The average length of the longest axon was
drastically increased in animals treated with 4Ig (2,875 ± 228 mm)
or MbCD (2,195 ± 335 mm) compared to its respective controls
(18 ± 7 mm and 128 ± 118 mm) (Figures 6C and 6D). Although
axons were rarely seen beyond the lesion site in controls,
many fibers in the 4Ig or MbCD group spanned beyond
3,000 mm of the lesion site (Figures 6E and 6F). We used a SCI
model of impact/compression injury in which both the dorsal
and ventral aspects of the spinal cord are simultaneously com-
pressed. The severity of SCI used in the present study results
in central cavitation of the gray matter and adjacent white matter
that severs all CST axons leaving a spared rim of subpial white
matter (Figure S6C). Moreover, in 4Ig and MbCD animals, we
observed fibers that displayed aberrant paths (Figure S6D),
also indicative of regeneration. To ensure that BDA fibers were
regenerating axons, we analyzed the cord from 4Ig (i.v. injec-
tion)-treated animals at different time points (n = 5 for each)
and found that fibers were significantly longer at 6 weeks when
compared to 4 weeks following injury (Figure 6G). In particular,
we observed a significantly higher number of fibers between 2
and 3 mm caudal from the lesion in 6-week versus 4-week ani-
mals (Figure 6H). We also examined cross-sections of the spinal
cord at 3 mm rostral and 5 mm caudal to the lesion. In sham an-
imals, spared fibers were apparent at both locations showing the
continuity of the CST in the uninjured spinal cord. In contrast, in
4Ig (i.v.)-treated animals, fibers were observed rostral to the
lesion, but not at 5 mm caudal to the lesion, indicating the lack
of spared fibers. In 4Ig (i.v.)- or MbCD (i.p.)-treated rats, labeled
fibers were detected at a maximal distance of 4 mm caudal to
the lesion site, suggesting that these fibers are regenerating and
not spared. Taken together, these findings suggest that
excluding Neogenin away from rafts promotes axonal regenera-
tion after SCI and the attendant functional recovery.
Neogenin Requires Lipid Rafts to Hamper Axonal
Regeneration after Optic Nerve Crush
It may be difficult to differentiate between spared and regenerat-
ing fibers in SCI; however, GAP-43 only stains regenerating fi-
bers, and the optic nerve crush model would be a confirmation
that our treatments promote axonal regeneration (Meyer et al.,
1994; Monnier et al., 2011). Following injury, animals received
i.v. injections of 4Ig or N-Raft, and axonal regeneration was
examined 21 days later (Figure 7). Regeneration was visualized
by GAP-43 immunostaining that only localizes to regenerating
adult RGC axons of the proximal and distal nerve stump (Meyer
et al., 1994; Monnier et al., 2011). In controls, few axons crossed
the lesion site within the optic nerve, and growth cones stopped
abruptly at the crush site (Figure 7A). Regenerating axons in
controls were limited to <250 mm in length, and an average of
408 regenerating axons per optic nerve were observed beyond
the lesion site (Figures 7A and 7E; <250 mm, 224 ± 36; 250–
500 mm, 108 ± 12; and >500 mm, 76 ± 24). In stark contrast, an-
imals treated with 4Ig showed increased regeneration beyondl Reports 8, 1146–1159, August 21, 2014 ª2014 The Authors 1153
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the lesion site and more pronounced axon sprouting in the prox-
imal segment of the nerve (Figures 7B and 7E). Quantification of
axon numbers by length showed that 4Ig significantly increased
the number of regenerating axons by 5.7-fold relative to controls
(Figures 7B and 7E; <250 mm, 1,134 ± 68; 250–500 mm, 640 ±
128; and >500 mm, 410 ± 64). Animals that received N-Raft
also showed robust regeneration beyond the lesion site to a de-
gree comparable to 4Ig (Figures 7C and 7E). Thus, both 4Ig and
N-Raft enhanced axon regeneration in the myelinated adult
CNS.
We next examined whether cholesterol depletion could pro-
mote regeneration after optic nerve crush. Axonal length was
measured in rats that were treated over a 28-day period with
MbCD, previously used to study metastasis in vivo (Grosse
et al., 1998) (Figures 7D and 7E). For all distances considered,
the average number of axons per section in animals treated
with MbCD (i.p. injection) was significantly higher than controls
by 7.1-fold (Figures 7D and 7E; <250 mm, 23.7 ± 1.2; 250–
500 mm, 10.7 ± 0.9; and >500 mm, 8.4 ± 1.4). We also examined
the intraretinal integrity of RGC axons after optic nerve crush to
look for signs of increased axon/soma preservation by our treat-
ments 4 weeks following injury. The cell bodies of surviving
RGCs with intact axons were visibly labeled with CTB-fluores-
cein isothiocyanate (FITC) (Figure S7C). Treatments with 4Ig,
N-Raft, and MbCD resulted in (1) thicker axon bundles
throughout the retina, and (2) increased labeling of RGC somata,
which is consistent with a role of these treatments in both cell
survival and axonal regeneration. Overall, these findings show
that Neogenin plays an important role in the failure of axons to
regenerate after optic nerve injury and that preventing its associ-
ation with lipid rafts results in robust axonal regeneration.
Because astroglia cells were not affected, the proregenerative
effect of our treatments most likely resulted from an effect on re-
generating axons (Figure S7). In summary, these data demon-
strate that altering Neogenin presence in lipid rafts promotes
axonal regeneration after CNS injury.
DISCUSSION
RGMa has two contradictory actions in the regenerating CNS,
i.e., it inhibits axonal growth, which is undesirable, and promotes
cell survival, which is valuable (Koeberle et al., 2010). Here, weFigure 5. Altering Neogenin Presence in Lipid Raft Promotes Function
(A–F) Behavioral assessment using the BBB (A andD),motor subscore (B and E), a
(i.v.) or MbCD (i.p.) resulted in marked functional improvement in spinal cord-injur
MbCD, n = 8) (*p < 0.005).
(G and H) Behavioral assessment using the BBB (G) and average number of foot
improvement in spinal cord-injured rats versus control. Data are average ± SEM
(I–M) Longitudinal sections of an injured spinal cord stained with the neuronal mark
rats after systemic treatment with (I) vehicle control, (J) 4Ig, and (K) MbCD. Arrow
betweenwhite and graymatter. Quantification of experiments presented in (I)–(K) s
in the number of spared neurons after SCI. For each animal, the absolute numbe
distance through the thickness of each cord encompassing equivalent gray mat
(N andO) Neu-N staining of cross-sections of injured spinal cords after intrathecal
(O) 4Ig. Arrowheads point to neurons.
(P) Quantification of experiments presented in (N) and (O) shows that intrathecal tre
SCI. Quantification at different distances to the lesion site is presented in Figure
Scale bars, 100 mm.
Celsolve this dilemma by developing an approach that inhibits the
RGMa receptor, Neogenin, to promote both cell survival and
axonal regeneration. We show that Neogenin is a constitutive
part of lipid rafts and that this association is required to inhibit
axons and induce apoptosis. Multiple approaches to prevent
Neogenin transport to rafts promoted axonal growth on inhibi-
tory RGMa and blocked Neogenin-induced apoptosis. Both
peptide-mediated blockade of Neogenin translocation into rafts
and cholesterol depletion to disrupt rafts improved axonal
regeneration in the injured optic nerve and the spinal cord.
Importantly, these strategies resulted in significant functional
recovery after SCI. Thus, our data uncover an unappreciated
role for lipid rafts and Neogenin in regeneration following CNS
injuries.
We identified an RGMa domain (N-Raft) that interacts with the
4Ig-Neogenin to regulate Neogenin targeting into lipid rafts. At
first glance, this mechanism resembles how DCC, TrkA, and
Neuropilin are recruited to rafts, i.e., when their respective
ligands Netrin-1, BDNF, and Sema3A are added to the medium,
they interact in transwith their receptors thereby increasing their
association with rafts (Guirland et al., 2004). However, unlike the
mechanism mentioned above, trafficking of Neogenin to rafts by
RGMa appears to require additional molecular mechanisms.
Indeed, both Neogenin and RGMa reside on the same mem-
branes, and we show that a cis interaction between these
proteins is necessary to localize Neogenin to rafts. A similar cis
interaction between EphA3 receptor and its ligand, ephrin, has
been reported, but it negatively regulates EphA3 (Carvalho
et al., 2006), which is in contrast to RGMa-Neogenin interaction,
which activates Neogenin, Thus, our data evoke a paradigm by
which an extracellular guidance cue ‘‘primes’’ its receptor
through a cis interaction.
BMPs have been shown to regulate axonal growth by (1) regu-
lating the expression of guidance cues such as ephrin/Eph pro-
teins (Sakuta et al., 2006) or (2) acting as a repulsive guidance
cue (Phan et al., 2010). Here, we uncover a role for BMPs in regu-
lating axonal growth by enabling Neogenin function. This para-
digmmay explain some recent studies, which at first view appear
contradictory. One study demonstrated that BMP2 and BMP4
injection activated Smad1, thereby promoting axonal regenera-
tion (Zou et al., 2009). However, another study showed that abol-
ishing BMP activity promoted regeneration (Matsuura et al.,al Recovery and Neuronal Survival after SCI
nd average number of footfalls (C and F) shows that systemic treatment with 4Ig
ed rats versus control (Ctrl). Data are average ± SEM (control, n = 7; 4Ig, n = 8;
falls (H) shows that intrathecal application of 4Ig resulted in marked functional
(control, n = 10; 4Ig, n = 10) (*p < 0.005).
er NeuN. The insets display peri-lesional neurons in the injured spinal cord from
s point to neurons after 4Ig and MbCD treatments. Dotted line indicates border
hows that treatment with (L) 4Ig and (M)MbCD resulted in a significant increase
r of neurons was quantitated from five sections at equivalent anterior-posterior
ter tissue.
treatment with 4Ig. The insets display cord from rats treatedwith (N) vehicle and
atment with 4Ig resulted in a significant increase in the number of neurons after
S5D. Data are average ± SEM (n = 8 animals/condition). *p < 0.001.
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Figure 6. Altering Neogenin Presence in
Lipid Rafts Promotes Axonal Regeneration
in the Myelinated Spinal Cord
To visualize axons from the CST, anterograde
axonal tracing with BDAwas performed at 6weeks
post-SCI.
(A) Top panel displays a control spinal cord after
injury. The insets represent higher magnifications.
The lesion cavity is presented on the left.
(B) Injured spinal cord treated with 4Ig. Tracing
with BDA revealed fibers caudal to the cavity in 4Ig
experiments, but not in Control. The longest re-
generating axons extended several millimeters
beyond the caudal end of the cavity. Arrows indi-
cate fibers. Arrowheads in the insets indicate
turning fibers. Scale bars, 100 mm.
(C and D) Average maximal length post-SCI
was increased following (C) 4Ig and (D) MbCD
treatments. Data are average ± SEM (n = 4 inde-
pendent rats/condition; three to four sections/rat).
*p < 0.001.
(E and F) The average number of regenerating
axons/section was measured, which shows a
greater number of regenerating axons in injured
rats treated with (E) 4Ig and (F) MbCD. Data are
average ± SEM (n = 4 independent rats/condition;
three to four sections/rat). *p < 0.005.
(G and H) Injured spinal cord treated with 4Ig for 4
or 6 weeks before animals were sacrificed and
axonal length was measured. (G) The average
axonal length was significantly greater at 6 weeks
when compared to 4 weeks. (H) The average
number of regenerating axons/section was mea-
sured, which shows a significantly higher number
of axons of 2–3 mm when cords were treated for
6 weeks when compared to 4 weeks. Data are
average ± SEM (n = 5 independent rats/condition;
three to four sections/rat). *p < 0.005.2008). Thus, activating and neutralizing the same pathway
seemed to promote regeneration. Our data reconcile this
discrepancy and suggest that the proregenerative effect of
BMP neutralization with Noggin may not result from a silencing
of the BMP/Smad pathway but rather from a neutralization of
the RGMa/Neogenin pathway.1156 Cell Reports 8, 1146–1159, August 21, 2014 ª2014 The AuthorsBecause cholesterol is an important
constituent of growing axons, it has
been assumed that it is necessary for
axonal growth/regeneration (Posse De
Chaves et al., 2000). Our data defy the
notion that cholesterol is merely a ‘‘build-
ing brick’’ required for the biogenesis
of axonal membranes. A recent study
suggests that cholesterol may directly
modulate growth by a Fyn-dependent
mechanism and thereby play an active
role in axonal elongation (Ko et al.,
2005). Interestingly, during peripheral
nerve regeneration, cholesterol synthesis
in the nerve is downregulated (Goodrum,
1990), which fits with our data indicatingthat lower cholesterol-levels in membranes promote regenera-
tion. There are other indications that lipid rafts may be a critical
regulator of axonal regeneration. For instance, the Nogo recep-
tor is a GPI-anchored protein and is naturally present in rafts
(Fournier et al., 2001). Ephrin-As, which are strong axon inhibi-
tors, are also GPI anchored and require oligomerization in rafts
Figure 7. Altering Neogenin Presence in
Lipid Rafts Promotes Axonal Regeneration
after Optic Nerve Injury
(A–D) GAP-43 immunostaining in longitudinal
sections of optic nerve at 21 days after optic nerve
crush and various treatments. Compared to con-
trols (A), altering Neogenin presence in lipid rafts
with (B) 4Ig and (C) N-Raft or (D) disrupting lipid
raft with MbCD enhances axonal regeneration
past the crush site (yellow dotted line) and into the
distal myelinated optic nerve. Arrows demarcate
some of the regenerating axons in each nerve
section. Inset images are higher-magnification
views of regenerating axons from the corre-
sponding section.
(E) Quantification of axonal length showing that
4Ig, N-Raft, and MbCD significantly enhanced
axonal regeneration after optic nerve injury. Data
are average ± SEM (n = 7 optic nerves/condition).
*p < 0.001.
Scale bar, 200 mm.to inhibit growing fibers. Therefore, several CNS inhibitors rely on
lipid rafts to prevent regeneration. Although the above evidence
was suggestive, our data demonstrate that cholesterol depletion
promotes regeneration.
Neutralizing inhibitory proteins is awell-established strategy to
promote regeneration. For instance, antibodies have been used
to neutralize myelin, Nogo-A, and RGMa, thus promoting some
recovery after injury (Hata et al., 2006). Thus far, none of theseCell Reports 8, 1146–1159,approaches has led to the development
of therapeutics, perhaps because be-
sides promoting regeneration, they also
have unwanted effects (e.g., promote
apoptosis). We present an alternative
strategy that counteracts inhibitory path-
ways by modifying receptor membrane
localization.
Because many receptors are present
in lipid rafts, treatment with MbCD will
not only affect Neogenin presence in
these structures. For instance, cyclodex-
trins could influence signaling of recep-
tors for Nogo, Semaphorin, and BDNF,
which are present in lipid rafts (Furne
et al., 2006; Guirland and Zheng, 2007).
This lack of specificity may prevent the
activation of pathways that could pro-
mote neuronal survival and regeneration
in the injured CNS. On the other hand,
this may well be an advantage because
it may allow for the neutralization of re-
ceptors for multiple growth inhibitors.
Regardless of the specificity of cyclo-
dextrin, the effects that we observed
strongly suggest that the benefit of
lipid raft depletion largely outweighs
some of its possible negative aspects
on regeneration.In the past decade, there has been some level of success in
promoting axonal regeneration after CNS injuries. In particular,
two studies obtained robust axonal regeneration after optic
nerve injury (Fischer et al., 2004; Sun et al., 2011). However,
although these studies demonstrate that regeneration is feasible
in the injured CNS, they will be difficult to translate into human
therapies because they utilized injection of lentiviral vectors
several weeks before injury (Fischer et al., 2004). Moreover, theAugust 21, 2014 ª2014 The Authors 1157
first study (Fischer et al., 2004) was done by knocking down
PTEN and SOCS3 together with ciliary neurotrophic factor injec-
tion. In the second study (Sun et al., 2011), regeneration
occurred when a DN-NogoR vector was injected together with
lens injury to ‘‘activate’’ RGCs. In contrast, we performed one
treatment at a time and initiated each strategy after injury. Never-
theless, the above-mentioned studies show that combinatorial
therapies potently induce regeneration. It will be important to
combine our treatment with other treatments. For instance,
combining our peptide treatments, which suppress RGMa inhibi-
tion, with treatments that will promote the intrinsic ability of neu-
rons to regenerate should result in robust regeneration.
EXPERIMENTAL PROCEDURES
Detailed procedures are presented in Supplemental Experimental Procedures.
Retinal Explants, Outgrowth Assay, and Immunolocalization
Poly-L-Lysine (Sigma-Aldrich; 10 mg/ml)-coated glass coverslips were treated
with Laminin (Invitrogen; 10 mg/ml) and RGMa proteins (5 mg/ml) and incubated
for 3 hr at room temperature. Temporal retinal explants were cultured on pro-
tein-coated surfaces for 18 hr. To disrupt rafts, explants were pretreated with
10mMMbCD for 12min or 2 U/ml CO for 1 hr at 37C. Explants were then fixed
with 4% paraformaldehyde and stained with Alexa 488 phalloidin. Fiber length
was quantified using Image-Pro 5.0. For immunolocalization, explants were
treated with CTB-FITC (C1655; Sigma-Aldrich; 10 mg/ml) and patched, fixed,
and stained with Neogenin antibody. RGCs were electroporated with RGMa-
His and cultured for 18 hr. The cells were fixed, and stained with Neogenin and
His-tag antibodies.
Lipid Raft Fractionation of Cells and Tecta
Injected chick E8 tecta (4Ig, 2 mg/ml; N-raft, 1 mg/ml; MbCD, 10 mM) or
transfected cells (Neogenin and RGMa) were collected 24 hr later, lysed,
and placed at the bottom of a sucrose density gradient (0.9-0.8-0.75-0.7-
0.6-0.5-0.4-0.2 M) and centrifuged at 38,000 rpm for 16 hr in a SW 60 rotor
(Beckman Instruments).
Spinal Cord Injury
The spinal cord was injured by clip compression at spinal cord level T8 with a
20 g force. The 4Ig or vehicle was injected intraspinally immediately following
SCI. Two injections (250 ng/ml, 3 ml each) were made 1 mm rostral and 1 mm
caudal to the lesion site and adjacent to themidline vein. Immediately following
SCI, the 4Ig-treated rats also received a 1 mg/kg dose of 4Ig i.v. via the intra-
jugular vein and subsequent i.v. injections weekly for 2more weeks. Rats in the
MbCDgroup received i.p. injection ofMbCD at 1,000mg/kg/week immediately
following SCI and then daily i.p. injections until sacrifice. Control rats received
equivalent vehicle volumes as described above.
Intrathecal Infusion
To assess local delivery of 4Ig, 19 adult female Wistar rats were injured and in-
jected rostral and caudal to the lesion site with 4Ig or PBS. Immediately after
the intraspinal injections, 4Ig or PBS was delivered intrathecally and then
continuously for 14 days (0.5 ml/hr) via the catheter and pump system.
Functional Analysis
Functional tests were performed before the injury, 1 day after, and then weekly
for 6 weeks post-SCI. Locomotor function was evaluated using the BBB loco-
motor rating scale. A score of zero (‘‘0’’) indicates no hindlimb movement; a
score of 21 indicates unimpaired locomotion as observed in control. Motor
subscores were determined to assess toe clearance, predominant paw posi-
tion, and absence of instability. A maximal motor subscore of seven means
normal locomotion.
Ladder walk analysis was done to assess fine motor functions. At 1 week
post-SCI and weekly thereafter, rats with a BBB score >11 were placed on
the horizontal ladder walk apparatus, and three test runs were recorded.1158 Cell Reports 8, 1146–1159, August 21, 2014 ª2014 The AuthorRecordings were analyzed in slowmotion; the number of footfalls per hindlimb
was recorded, and the average was calculated for each rat per week.
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Supplemental Information includes Supplemental Experimental Procedures
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